Investigating how SGLT2 inhibitors affect heart health in women with HIV
Official title: Effects of SGLT2 Inhibition on Coronary Flow Reserve and Other Key Indices Relevant to Type 2 Myocardial Infarction Risk among Women with HIV
Funded at Massachusetts General Hospital · NIH-11006470 · Data updated 2026-11-12
This study is looking at how a type of medication called SGLT2 inhibitors can help protect the hearts of women living with HIV who are at risk for heart attacks, and it will involve giving some women the medication and others a placebo to see how it affects their heart health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $771,613 |
| NIH project number | 1R01HL170905-01A1 |
| Project ID | NIH-11006470 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women living with HIV who are on antiretroviral therapy and at risk for myocardial infarction.
✕Less likely to help
Patients who are not living with HIV or those who do not have risk factors for myocardial infarction may not benefit from this research.
What this research studies
This research focuses on women living with HIV who are at a higher risk of heart attacks. It aims to explore how a specific class of medications, known as SGLT2 inhibitors, can improve heart function and reduce risks associated with type 2 myocardial infarction. The study will involve a randomized controlled trial where participants will receive either the medication or a placebo, and their heart health will be monitored using advanced imaging techniques. By understanding the effects of these medications, the research seeks to identify new ways to protect heart health in this vulnerable population.
Why it matters
Potential benefit: If successful, this research could lead to improved heart health and reduced risk of heart attacks for women living with HIV.
How similar studies have gone: Previous research has shown that SGLT2 inhibitors can improve heart function in certain populations, but this specific application in women with HIV is novel.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Zanni, Markella V. — Massachusetts General Hospital
- Study coordinator: Zanni, Markella V.
Related research
Other NIH-funded projects on the same topics.
-
Anti-inflammatory signaling of a key protein in heart attack recovery
A study in people who have had a heart attack is exploring how a macrophage protein called Tristetraprolin may reduce inflammation and help protect heart tissue.
-
Targeting RIPK3 to reduce heart damage after a heart attack
This grant studies a specific cell-death pathway (RIPK3) to protect the heart after a heart attack, with the goal of reducing damage and improving recovery.
-
mRNA lipid nanoparticles to help heart attack patients grow healthier blood vessels
A heart-attack study tests a new treatment that uses messenger RNA delivery with tiny fat bubbles to promote normal blood vessel growth in damaged heart tissue.
-
Targeted nanotherapy to calm inflammation, grow new blood vessels, and prevent scarring after a heart attack
A new treatment approach uses engineered secretions from immune cells delivered early after a heart attack to reduce inflammation, promote blood vessel growth, and limit scarring to protect heart function.
-
Why heart attacks and strokes affect people differently across places and races
This project follows adults across the U.S. to see how lifelong social and neighborhood factors shape heart attacks, heart failure, and recovery, with attention to Black adults and regions with high disease rates.
-
Real-time multi-lead ECG from wearables to help detect heart attacks early
A new AI-based approach uses everyday wearable sensors to turn simple PPG signals into multi-lead ECG data to monitor for heart attacks in real time, even outside the clinic.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.